Cabtreo (Adapalene/Benzoyl/Clindamycin) Patent Expiration, LOE Window & CMS Spending
Cabtreo (Adapalene/Benzoyl/Clindamycin) by Bausch Health: FDA Orange Book LOE 2040-12-28, 0 AB generics, $4.5M 2024 CMS Part D & Medicaid spend, and $950 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bausch Health |
| FDA Application & Pathway | N216632 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-12-28 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $4.5M |
| 2024 Medicare Part D Spend | $197K |
| 2024 Medicaid Spend | $4.3M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($950 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bausch Health / Bausch + Lomb FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBausch Health / Bausch + Lomb Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bausch Health / Bausch + Lomb 401(k) & Form 5500 Planerisa.meruai.co →